Suppr超能文献

在近期骨关节炎结构改变药物试验中,轻度至中度疼痛缓解并非全伸膝位X线片关节间隙变窄评估的混杂因素。

Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials.

作者信息

Pavelka K, Bruyere O, Rovati L C, Olejárova M, Giacovelli G, Reginster J-Y

机构信息

Department of Medicine and Rheumatology, Charles University, Prague, Czech Republic.

出版信息

Osteoarthritis Cartilage. 2003 Oct;11(10):730-7. doi: 10.1016/s1063-4584(03)00166-3.

Abstract

OBJECTIVE

To assess whether improvement in knee pain biased the determination of the structure-modifying effect reported for glucosamine sulfate in two recent 3-year, randomised, placebo-controlled clinical trials, in which conventional standing antero-posterior full extension knee radiographs were used for the measurement of joint space narrowing, and in which pain relief might have improved knee full extension.

DESIGN

Patients completing the 3-year treatment course were selected based on a WOMAC pain decrease at least equal to the mean improvement in the glucosamine sulfate arms in either of the original studies, irrespective of treatment with glucosamine sulfate or placebo (drug responders or placebo responders). In a second approach, 3-year completers were selected if their baseline standing knee pain (item #5 of the WOMAC pain scale) was 'severe' or 'extreme' and improved by any degree at the end of the trials. In both cases, changes in minimum joint space width were compared between treatment groups.

RESULTS

Global knee pain was mild-to-moderate in the two study populations and in all patient subsets identified. There were obviously more pain improvers in the glucosamine sulfate subsets (N=76 in the two studies combined) than in the placebo subsets (N=57), but WOMAC pain scores improved to the same extent, which was as large as over 50% relative to baseline. Nevertheless, the placebo subsets in both studies underwent an evident mean (SD) joint space narrowing, which in the pooled analysis of both studies was -0.22 (0.80) mm, and was not observed with glucosamine sulfate: +0.15 (0.60) mm (P=0.003 vs placebo). Similar results were found in the smaller subsets with > or = severe baseline standing knee pain that improved after 3 years, with a joint space narrowing nevertheless of -0.28 (0.76) mm with placebo (N=26), not observed with glucosamine sulfate: +0.21 (0.68) mm (N=31; P=0.014 vs placebo).

CONCLUSIONS

Knee pain relief did not bias the report of a structure-modifying effect of glucosamine sulfate in two recent long-term trials using conventional standing antero-posterior radiographs, possibly due to the mild-to-moderate patient characteristics.

摘要

目的

在两项近期开展的为期3年的随机、安慰剂对照临床试验中,评估膝关节疼痛的改善是否会影响硫酸氨基葡萄糖结构改善作用的判定。这两项试验使用常规站立位前后位全伸膝X线片测量关节间隙变窄情况,且疼痛缓解可能改善了膝关节的完全伸展。

设计

根据西部安大略和麦克马斯特大学骨关节炎指数(WOMAC)疼痛评分降低情况,选择完成3年治疗疗程的患者,降低程度至少与两项原始研究中硫酸氨基葡萄糖治疗组的平均改善程度相同,无论其接受的是硫酸氨基葡萄糖还是安慰剂治疗(药物反应者或安慰剂反应者)。第二种方法是,选择3年治疗完成者,条件是其基线站立位膝关节疼痛(WOMAC疼痛量表第5项)为“重度”或“极重度”,且在试验结束时疼痛有任何程度的改善。在这两种情况下,比较治疗组之间最小关节间隙宽度的变化。

结果

在两个研究人群以及所有确定的患者亚组中,膝关节总体疼痛为轻至中度。硫酸氨基葡萄糖亚组(两项研究合并共76例)中疼痛改善者明显多于安慰剂亚组(57例),但WOMAC疼痛评分改善程度相同,相对于基线改善幅度高达50%以上。然而,两项研究中的安慰剂亚组均出现明显的平均(标准差)关节间隙变窄,两项研究的汇总分析结果为-0.22(0.80)mm,而硫酸氨基葡萄糖组未观察到变窄:+0.15(0.60)mm(与安慰剂相比,P=0.003)。在3年后基线站立位膝关节疼痛≥重度且有所改善的较小亚组中也发现了类似结果,安慰剂组关节间隙变窄为-0.28(0.76)mm(n=26),硫酸氨基葡萄糖组未观察到变窄:+0.21(0.68)mm(n=31;与安慰剂相比,P=0.014)。

结论

在两项近期使用常规站立位前后位X线片的长期试验中,膝关节疼痛缓解并未影响硫酸氨基葡萄糖结构改善作用的报告,这可能归因于患者轻至中度的疼痛特征。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验